Blueprint Medicines Corp. Company Profile (NASDAQ:BPMC)

Analyst Ratings

Consensus Ratings for Blueprint Medicines Corp. (NASDAQ:BPMC) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $30.60 (42.06% upside)

Analysts' Ratings History for Blueprint Medicines Corp. (NASDAQ:BPMC)
Show:
DateFirmActionRatingPrice TargetActions
5/27/2016Raymond James Financial Inc.Initiated CoverageOutperform$23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/15/2016WedbushReiterated RatingOutperform$41.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$54.00 -> $37.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$54.00 -> $37.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Goldman Sachs Group Inc.Lower Price Target$26.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for Blueprint Medicines Corp. (NASDAQ:BPMC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/10/2016Q116($0.70)($0.57)$3.24 million$6.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/11/2016Q415($0.53)($0.58)$2.85 million$4.64 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q3($0.54)($0.47)$1.83 million$3.43 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Blueprint Medicines Corp. (NASDAQ:BPMC)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.82)($0.82)($0.82)
Q3 20161($0.89)($0.89)($0.89)
Q4 20161($0.99)($0.99)($0.99)
Q1 20171($1.15)($1.15)($1.15)
Q2 20171($1.18)($1.18)($1.18)
Q3 20171($1.38)($1.38)($1.38)
Q4 20171($1.62)($1.62)($1.62)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Blueprint Medicines Corp. (NASDAQ:BPMC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Blueprint Medicines Corp. (NASDAQ:BPMC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/3/2016Jeffrey W AlbersCEOSell17,000$20.03$340,510.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/13/2016Christoph LengauerInsiderSell15,872$20.01$317,598.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/12/2016Christoph LengauerInsiderSell18,853$20.14$379,699.42View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/6/2016Jeffrey W AlbersCEOSell17,000$20.42$347,140.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2015Christoph LengauerinsiderSell31,119$25.05$779,530.95View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/27/2015Fmr LlcInsiderSell287,415$21.48$6,173,674.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2015Fmr LlcInsiderSell161,271$20.14$3,247,997.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/23/2015Fmr LlcInsiderSell189,572$20.15$3,819,875.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2015Fmr LlcInsiderSell237,218$19.76$4,687,427.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2015Fmr LlcInsiderSell27,490$20.60$566,294.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2015Christoph LengauerinsiderSell84,998$21.05$1,789,207.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Blueprint Medicines Corp. (NASDAQ:BPMC)
DateHeadline
06/28/16 07:18 AMBlueprint Medicines Corp. breached its 50 day moving average in a Bearish Manner : BPMC-US : June 28, 2016 -
06/24/16 03:31 PMBLUEPRINT MEDICINES CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/20/16 01:07 PMETF’s with exposure to Blueprint Medicines Corp. : June 20, 2016 -
06/07/16 08:32 PMBlueprint Medicines Corporation (NASDAQ:BPMC) Trading Up – Insider Trading Activity
06/07/16 04:29 PMETF’s with exposure to Blueprint Medicines Corp. : June 7, 2016 -
06/02/16 08:59 AMBlueprint Medicines Corp. :BPMC-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 -
06/01/16 03:25 PMBlueprint Medicines to Present at Upcoming Investor Conferences in June - [at noodls] - CAMBRIDGE, Mass., June 1, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined ...
05/27/16 07:20 AMCoverage initiated on Blueprint Medicines by Raymond James -
05/26/16 07:45 AMEarnings Review and Stock Rundown for Blueprint Medicines Corp (NASDAQ:BPMC) - Wall Street Hints and News - Earnings Review and Stock Rundown for Blueprint Medicines Corp (NASDAQ:BPMC)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Blueprint Medicines Corp (NASDAQ:BPMC) to ...and more »
05/26/16 07:45 AMBlueprint Medicines Corp (NASDAQ:BPMC) Closes At $18.23 - RealistInvestor.com - Blueprint Medicines Corp (NASDAQ:BPMC) Closes At $18.23RealistInvestor.comThe technical analysis of Blueprint Medicines Corp (NASDAQ:BPMC) stock highlights the stock is $0.84 points away +4.86% from its 50-day MA of $17.36. It is $-0.73 or -3.88% away $18.93, the 200-day Moving Average (MA) of stock. Yesterday, the stock of ...
05/23/16 04:49 PMBlueprint Medicines Corp. – Value Analysis (NASDAQ:BPMC) : May 23, 2016 -
05/20/16 07:06 AMBlueprint Medicines Corp. breached its 50 day moving average in a Bullish Manner : BPMC-US : May 20, 2016 -
05/11/16 01:44 PMEdited Transcript of BPMC earnings conference call or presentation 10-May-16 12:00pm GMT -
05/10/16 07:00 AMBlueprint Medicines Corp Earnings Call scheduled for 8:00 am ET today -
05/10/16 06:26 AMBlueprint Medicines reports 1Q loss -
05/10/16 06:18 AMBlueprint Medicines Reports First Quarter 2016 Financial Results - [at noodls] - CAMBRIDGE, Mass., May 10, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined ...
05/10/16 06:17 AMBLUEPRINT MEDICINES CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and -
05/10/16 06:07 AMQ1 2016 Blueprint Medicines Corp Earnings Release - Time Not Supplied -
05/08/16 01:56 PMBlueprint Medicines Corporation (NASDAQ:BPMC) Broker Price Targets For The Coming Week - Share Trading News - Blueprint Medicines Corporation (NASDAQ:BPMC) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Blueprint Medicines Corporation (NASDAQ:BPMC). The latest reports which are currently in issue on Sunday 8th of May state 0 analysts have a rating of “strong buy”, 0 ...
05/07/16 02:02 PMBlueprint Medicines Corp (BPMC): Biotechnology Value Fund Reports 10.4% Stake - Insider Monkey (blog) - Insider Monkey (blog)Blueprint Medicines Corp (BPMC): Biotechnology Value Fund Reports 10.4% StakeInsider Monkey (blog)According to a recent 13G filing with the US Securities and Exchange Commission, Mark Lampert's Biotechnology Value Fund L. P. owns 2.84 million common shares of Blueprint Medicines Corp (NASDAQ:BPMC), which amass 10.4% of the company's ...Blueprint Medicines Corp (BPMC) Set to Announce Quarterly Earnings on TuesdayWeb Breaking NewsBlueprint Medicines Corporation (NASDAQ:BPMC) - Broker UpdateRisers & FallersBlueprint Medicines Corporation (NASDAQ:BPMC) Shorts Decreased by 3.07% After Short CoveringFranklin IndependentEnterprise Leader -Share Trading Newsall 8 news articles »
05/05/16 02:40 PMBlueprint Medicines Corp (BPMC): Biotechnology Value Fund Reports 10.4% Stake -
05/03/16 07:30 AMBlueprint Medicines to Report First Quarter 2016 Financial Results on Tuesday, May 10, 2016 - [at noodls] - CAMBRIDGE, Mass., May 3, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined ...
04/28/16 12:03 PMETF’s with exposure to Blueprint Medicines Corp. : April 28, 2016 -
04/27/16 07:36 AMBlueprint Medicines Corp. breached its 50 day moving average in a Bearish Manner : BPMC-US : April 27, 2016 -
04/24/16 01:46 PMBlueprint Medicines Corp (NASDAQ:BPMC) Share Rating Recap - The Post - Blueprint Medicines Corp (NASDAQ:BPMC) Share Rating RecapThe PostShares of Blueprint Medicines Corp (NASDAQ:BPMC) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly from ...and more »
04/22/16 07:43 PMA year after the state's biggest biotech IPO, Blueprint Medicines maps out a plan -
04/17/16 01:51 PMStock Update (NASDAQ:BPMC): Blueprint Medicines Corp Appoints Lynn Seely, MD to Board of Directors - Smarter Analyst - The Vista VoiceStock Update (NASDAQ:BPMC): Blueprint Medicines Corp Appoints Lynn Seely, MD to Board of DirectorsSmarter AnalystBlueprint Medicines Corp (NASDAQ:BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today announced the appointment of Lynn Seely, M.D. to its board of directors. Dr. Seely ...Blueprint Medicines Corp (BPMC) Insider Christoph Lengauer Sells 15872 Shares of StockThe Vista VoiceBlueprint Medicines Corp (BPMC) Insider Sells $317598.72 in StockMas Market NewsBlueprint Medicines Corp (BPMC) Files Form 4 Insider Selling : Christoph Lengauer Sells 15872 SharesMarket DigestWeb Breaking Newsall 5 news articles »
04/16/16 01:54 PMBlueprint Medicines Corp (NASDAQ:BPMC) Analyst Recommendation Outlook - Clinton Financial - Clinton FinancialBlueprint Medicines Corp (NASDAQ:BPMC) Analyst Recommendation OutlookClinton FinancialCovering analysts usually give Buy, Sell and Hold recommendations along with guidance and company earnings estimates. There are 2 analysts providing ratings for Blueprint Medicines Corp (NASDAQ:BPMC). 3 have given the stock a “Strong Buy”, 0 rate it ...and more »
04/15/16 03:31 PMBLUEPRINT MEDICINES CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi -
04/15/16 07:19 AMBlueprint Medicines Appoints Lynn Seely, M.D. to Board of Directors - [at noodls] - CAMBRIDGE, Mass., April 15, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined ...
04/09/16 01:55 PMIs Blueprint Medicines Corp (NASDAQ:BPMC) a Consensus Buy? - Clinton Financial - Is Blueprint Medicines Corp (NASDAQ:BPMC) a Consensus Buy?Clinton FinancialEquity research firms covering public U.S companies have a workforce of analysts dedicating their time covering the most popular stocks. Their reports are delivered to institutional investors in order to help make investment decisions. The information ...and more »
04/09/16 01:55 PMNew Analyst Ratings On Blueprint Medicines Corporation (NASDAQ:BPMC) - Risers & Fallers - New Analyst Ratings On Blueprint Medicines Corporation (NASDAQ:BPMC)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Blueprint Medicines Corporation (NASDAQ:BPMC). The latest broker reports which are currently outstanding on Friday 8th of April state 1 analyst has a rating of “strong buy ...
04/08/16 07:26 AMWill Blueprint Medicines (BPMC) Continue to Surge Higher? -
04/07/16 10:37 PMPartner Fund Management Has Confidence In Blueprint Medicines Corp (BPMC) -
04/05/16 01:56 PMAnalyst Ratings Check Blueprint Medicines Corp (NASDAQ:BPMC) - Business Standard Tribune - Analyst Ratings Check Blueprint Medicines Corp (NASDAQ:BPMC)Business Standard TribuneCovering sell-side analysts have an average rating of 1 on shares of Blueprint Medicines Corp (NASDAQ:BPMC). This Zacks Research number is compiled from analysts that they have taken into consideration. This consensus rating lands on a 1 to 5 scale.and more »
04/05/16 01:56 PMBlueprint Medicines Corporation (NASDAQ:BPMC) Latest Broker Coverage - Risers & Fallers - Blueprint Medicines Corporation (NASDAQ:BPMC) Latest Broker CoverageRisers & FallersA number of investment brokers have recently updated their price targets on shares of Blueprint Medicines Corporation (NASDAQ:BPMC). According to the latest broker reports outstanding on Tuesday 5th of April, 1 analyst has a rating of “strong buy”, ...
04/05/16 01:56 PMCan Shares Of Blueprint Medicines Corp (NASDAQ:BPMC) Touch $41? - Stocks Daily - Can Shares Of Blueprint Medicines Corp (NASDAQ:BPMC) Touch $41?Stocks DailyAs per Zacks Research report, the stock of Blueprint Medicines Corp (NASDAQ:BPMC) have been placed the high price target of $54. The brokerages have the price estimate fixed at $ 47.5. This indicates the expert opinion of 2 brokerages that have ...Blueprint Medicines to Present at 15th Annual Needham Healthcare ConferencePR Newswire (press release)all 2 news articles »
04/05/16 07:20 AMBlueprint Medicines to Present at 15th Annual Needham Healthcare Conference - [at noodls] - CAMBRIDGE, Mass., April 5, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined ...
04/04/16 01:49 PMCompany Shares of Blueprint Medicines Corporation (NASDAQ:BPMC) Rally 11.31% - Street Edition - Company Shares of Blueprint Medicines Corporation (NASDAQ:BPMC) Rally 11.31%Street EditionBlueprint Medicines Corporation (NASDAQ:BPMC) has climbed 11.31% in the past week and advanced 3.68% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 9.34% and the outperformance has advanced to 0.04% for ...After Last Week What Do Analysts Think Of Blueprint Medicines Corporation (NASDAQ:BPMC)Share Trading NewsGoldman Sachs rated Blueprint Medicines Corp (NASDAQ:BPMC) to Target Down, Sets Target Price to $15The Duncan Independent (press release) (blog)all 3 news articles »
04/03/16 01:42 PMGoldman Sachs rated Blueprint Medicines Corp (NASDAQ:BPMC) to Target Down, Sets Target Price to $15 - The Duncan Independent (press release) (blog) - Goldman Sachs rated Blueprint Medicines Corp (NASDAQ:BPMC) to Target Down, Sets Target Price to $15The Duncan Independent (press release) (blog)Blueprint Medicine Corp (NASDAQ:BPMC) target price was lowered by Goldman Sachs on Feb 23rd, 2016. The stock's target price was lowered, and went from $26.00 to $15.00. Deviations of actual gains from forecast numbers have a stong impact on the ...After Last Week What Do Analysts Think Of Blueprint Medicines Corporation (NASDAQ:BPMC)Share Trading Newsall 2 news articles »
04/02/16 01:59 PMShould Investors Buy Blueprint Medicines Corp (NASDAQ:BPMC)? - Clinton Financial - Should Investors Buy Blueprint Medicines Corp (NASDAQ:BPMC)?Clinton FinancialOut of the 2 analysts covering shares of Blueprint Medicines Corp (NASDAQ:BPMC), 3 rate it a “Strong Buy”, 0 rate it a “Buy”, 0 are advising to Hold the shares and 0 are saying “Sell”. Each recommendation can be mapped to an integer using a 1 to 5 scale.and more »
03/31/16 02:02 PMBvf Incil buys $38.8 Million stake in Blueprint Medicines Corp (BPMC) - The Sussex Pilot - Bvf Incil buys $38.8 Million stake in Blueprint Medicines Corp (BPMC)The Sussex PilotBlueprint Medicines Corp (BPMC) : Bvf Incil scooped up 575,805 additional shares in Blueprint Medicines Corp during the Q4 period, according to a recent disclosure to the SEC. The investment management firm now holds a total of 2,278,459 shares of ...and more »
03/30/16 01:58 PMBlueprint Medicines Corporation (BPMC) Short Interest Disclosure - The Sussex Pilot - Blueprint Medicines Corporation (BPMC) Short Interest DisclosureThe Sussex PilotBlueprint Medicines Corporation (NASDAQ:BPMC) has witnessed a drop of 8% or 152,993 shares in its short figure. The short interest diminution took it from 1,914,316 on February 29,2016 to 1,761,323 on March 15,2016. In terms of floated shares, the ...and more »
03/29/16 01:55 PMAverage Rating Watch Blueprint Medicines Corp (NASDAQ:BPMC) - Business Standard Tribune - Average Rating Watch Blueprint Medicines Corp (NASDAQ:BPMC)Business Standard TribuneStreet analysts that cover Blueprint Medicines Corp (NASDAQ:BPMC) presently have an average broker rating of 1 on the stock. This average rating comes from Zacks Research compiling polled analyst ratings taken into consideration. The average rating ...and more »
03/26/16 01:50 PMBlueprint Medicines Corporation (NASDAQ:BPMC) Broker Updates - Risers & Fallers - Blueprint Medicines Corporation (NASDAQ:BPMC) Broker UpdatesRisers & FallersA number of investment brokers have recently updated their price targets on shares of Blueprint Medicines Corporation (NASDAQ:BPMC). According to the latest broker reports outstanding on Thursday 24th of March, 1 analyst has a rating of “strong buy”, ...Blueprint Medicines Corp (NASDAQ:BPMC) Street Rating in FocusUptick Analystall 2 news articles »
03/25/16 01:58 PMCan Shares Of Blueprint Medicines Corp (NASDAQ:BPMC) Hit $54? - Stocks Daily - Can Shares Of Blueprint Medicines Corp (NASDAQ:BPMC) Hit $54?Stocks DailyZacks Research report illustrate that the shares of Blueprint Medicines Corp (NASDAQ:BPMC) have been assigned an upbeat price target of $54 by the sell-side analysts. Investment Groups surveyed by Zacks have set the target price of the stock at $47.5.and more »
03/23/16 01:22 PMLooking Ahead to Earnings for Blueprint Medicines Corp (NASDAQ:BPMC) - RiversideGazette.com - Looking Ahead to Earnings for Blueprint Medicines Corp (NASDAQ:BPMC)RiversideGazette.comInvestors and analysts will be looking ahead to Blueprint Medicines Corp (NASDAQ:BPMC)'s next earnings report which is slated to be released sometime on or around 2016-06-09 for the period ending on 2016-03-31. Street analysts have a consensus EPS ...and more »
03/22/16 08:20 AMBio-Techne Buys Zephyrus, Boosts Protein Platforms Division -
03/20/16 01:29 PMNext Weeks Broker Price Targets For Blueprint Medicines Corporation (NASDAQ:BPMC) - Risers & Fallers - Next Weeks Broker Price Targets For Blueprint Medicines Corporation (NASDAQ:BPMC)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Blueprint Medicines Corporation (NASDAQ:BPMC). The latest broker reports which have been released state 1 analyst has a rating of “buy”, 2 analysts “outperform”, 1 ...FY2019 EPS Estimates for Blueprint Medicines Corp Lifted by Wedbush (BPMC)The Hilltop NewsBlueprint Medicines Corporation (NASDAQ:BPMC): Analyst Targets For The Coming WeekShare Trading NewsBlueprint Medicines Corp (BPMC) Stock Rating Reaffirmed by WedbushThe Vista VoiceClinton Financial -Street Editionall 14 news articles »
03/18/16 03:18 PMBLUEPRINT MEDICINES CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Ot -

Social

About Blueprint Medicines Corp.

Blueprint Medicines Corp. logoBlueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options. The Company has developed a small molecule drug pipeline in cancer and a genetic disease. The Company's drug candidate, BLU-285, targets KIT Exon 17 mutants and PDGFRa D842V, which are abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. It is engaged in developing BLU-285 for patients with systemic mastocytosis (SM), a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor (GIST). Its drug candidate, BLU-554, targets FGFR4, a kinase that is aberrantly activated and is a driver of disease in a defined subset of patients with hepatocellular carcinoma (HCC).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BPMC
  • CUSIP:
Key Metrics:
  • Previous Close: $21.54
  • 50 Day Moving Average: $20.02
  • 200 Day Moving Average: $18.04
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $584.62M
  • Beta: 1.62
  • Current Year EPS Consensus Estimate: $-3.03 EPS
  • Next Year EPS Consensus Estimate: $-4.13 EPS
Additional Links:
Blueprint Medicines Corp. (NASDAQ:BPMC) Chart for Friday, July, 29, 2016